Video

Dr. Shore on study of patient preference between darolutamide and enzalutamide in mCRPC

Author(s):

Urology Times staff
Conference|ASCO Annual Meeting

Neal D. Shore, MD, discusses results from the phase 2 ODENZA trial presented at the 2021 ASCO Annual Meeting. The study is a prospective, randomized, open-label, multicenter, crossover, trial that assessed patient preference between darolutamide (Nubeqa) and enzalutamide (Xtandi) in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer. Shore is medical director of the Carolina Urologic Research Center.

Related Videos
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Related Content
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
November 18th 2024

Expert robotic surgeon discusses da Vinci 5, advances in urologic surgery

Ronney Abaza, MD, FACS
"It's actually a very exciting time to be a robotic surgeon," says Ronney Abaza, MD, FACS.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 16th 2024

Expert discusses current trials in bladder cancer to watch for

Jason M. Hafron, MD, CMO
"Bladder cancer is exploding. [It] is exciting, it's changing, and we're just at the start of this," says Jason M. Hafron, MD, CMO.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Blur image of hospital | Image Credit: © jakkapan - stock.adobe.com
November 15th 2024

Gautam Jayram, MD, on the top 5 things to know in bladder and kidney cancer

Gautam Jayram, MD
"We...talked a little bit about BCG-unresponsive disease, which is a really hot topic; a lot of trials and a lot of data are coming there," says Gautam Jayram, MD.
Prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
November 15th 2024

Scott Eggener, MD, on a pragmatic approach to prostate cancer innovations

Benjamin P. Saylor
“You have to be balanced in what to embrace vs what not. It is easy to be wowed by new things," said Scott Eggener, MD.
© 2024 MJH Life Sciences

All rights reserved.